Myeloma multiplex with pulmonary dissemination

Brankica Terzić; Djoko Maksić; Vesna Škuletić; Dejan Pilčević; Mirjana Mijušković; Zoran Čukić; Katarina Obrenčević; Marijana Petrović; Jelena Tadić - Pilčević; Milica Petrović

doi:10.2298/1809

Brankica Terzić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Djoko Maksić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Vesna Škuletić Insitute of Pathology, Military Medical Academy, Belgrade, Serbia
Dejan Pilčević Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Mirjana Mijušković Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Zoran Čukić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Katarina Obrenčević Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Marijana Petrović Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Jelena Tadić - Pilčević Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Milica Petrović Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/1809

Keywords: multiple myeloma, neoplasm metastasis, lung, plasma cells,

Abstract

Introduction. Multiple myeloma is a hemathological malignancy characterized by the clonal proliferation of plasma cells in the bone the marrow. Extramedullary dissemination of multiple myeloma is uncommon. In several cases only, the multiple myeloma malignant plasma cells had diseminated to the lung parenchyma. Case report. We presented a case of multiple myeloma with lung plasmacytoma, in a 79-year-old patient, hospitalized for febrility and infiltrative mass in the right lung. Two months before the patient was admitted, because of developing terminal renal failure, hemodialysis treatment had started three times a week. Since then, the patient was oliguric, but because of febrility and hemoptysis that appeared, at first he was treated with dual antibiotic therapy which resulted in temporary improvement of his general condition, but pleural effusion remained. After thoracocentesis, followed by myelogram, the multiple myeloma diagnosis was established. Conclusion. In patients of middle and older age, with general weakness, exhaustion, loss of weight, renal failure which progresses to the end stage rapidly, if symptoms of respiratory tract occur, consider this uncommon disease – extramedullary dissemination of multiple myeloma.

Author Biography

Brankica Terzić, Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia

Nefrologija

References

Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis.QJM 2007; 100(10): 635−40.

Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple mye-loma. Leukemia 2009; 23(9): 1545−56.

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78(1): 21−33.

Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127(3): 299−304.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statis-tics, 2009. CA Cancer J Clin 2009; 59(4): 225−49

Turesson I, Velez R, Kristinsson SY, Landgren O, Patterns of mul-tiple myeloma during the past 5 decades: Stable incidence rates for all age groups in the population but rapidly changing age distribution in the Clinic Mayo Clin Proc 2010; 85(3): 225–30.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.

Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schrat-zenstaller B, et al. Extramedullary plasmacytoma: tumour occur-rence and therapeutic concepts. Cancer 1999; 85(11): 2305–14.

Haubitz M, Peest D. Myeloma-new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 2006; 21(3): 582−90.

Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an in-dependent risk factor for progression of smoldering (asymp-tomatic) multiple myeloma. Blood 2008; 111(2): 785−9.

Chejfec G, Natarelli J, Gould VE. "Myeloma lung"-a previously unreported complication of multiple myeloma. Hum Pathol 1983; 14(6): 558−61.

Marisavljevic D, Markovic O, Cemerkic-Martinovic V, Ponomarev D. Plasmacytoma of the lung: an indolent disease resistant to conventional myeloma treatment: report of a case. Med Oncol 2005; 22(2): 207−10.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for se-rum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23(2): 215−24.

Wong PW, Stefanec T, Brown K, White DA. Role of fine-needle aspirates of focal lung lesions in patients with hematologic malignancies. Chest 2002; 121(2): 527−32.

Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25(9): 1121−8.

Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D. Pleural effusions in hematologic malignancies. Chest 2004; 125(4): 1546−55.

Maachi M, Fellahi S, Diop ME, Francois T, Capeau J, Bastard JP. Pleural effusion as a first sign of Ig D lambda multiple myelo-ma. Ann Med Interne (Paris) 2003; 154(1): 70−2. (French)